Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Convertible Debt (2017 - 2021)

Historic Convertible Debt for Neurocrine Biosciences (NBIX) over the last 5 years, with Q3 2021 value amounting to $330.7 million.

  • Neurocrine Biosciences' Convertible Debt changed N/A to $330.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $330.7 million, marking a year-over-year change of. This contributed to the annual value of $317.9 million for FY2020, which is 2223.58% down from last year.
  • Per Neurocrine Biosciences' latest filing, its Convertible Debt stood at $330.7 million for Q3 2021.
  • Over the past 5 years, Neurocrine Biosciences' Convertible Debt peaked at $414.1 million during Q1 2020, and registered a low of $317.9 million during Q4 2020.
  • For the 5-year period, Neurocrine Biosciences' Convertible Debt averaged around $370.2 million, with its median value being $374.2 million (2018).
  • Per our database at Business Quant, Neurocrine Biosciences' Convertible Debt soared by 525.25% in 2020 and then plummeted by 2224.1% in 2021.
  • Over the past 5 years, Neurocrine Biosciences' Convertible Debt (Quarter) stood at $369.6 million in 2017, then grew by 5.11% to $388.5 million in 2018, then rose by 5.23% to $408.8 million in 2019, then fell by 22.24% to $317.9 million in 2020, then rose by 4.03% to $330.7 million in 2021.
  • Its Convertible Debt was $330.7 million in Q3 2021, compared to $326.3 million in Q2 2021 and $322.0 million in Q1 2021.